Marcus Schindler

Novo Nordisk’s chief scientific officer and executive VP of research and early development, focusing on GLP-1s and other innovative therapies.

Best podcasts with Marcus Schindler

Ranked by the Snipd community

Dec 13, 2024 • 33min

Novo Nordisk’s chief scientific officer looks to the future of GLP-1s

Marcus Schindler, Novo Nordisk’s chief scientific officer and executive VP of research, discusses the breakthrough success of GLP-1 agonists like semaglutide in treating Type 2 diabetes and obesity. He reveals exciting innovations in dosing strategies and emerging applications in neurodegenerative diseases. Schindler also highlights the integration of psi RNA technology for better chronic disease management and the transformative impact of AI on drug development. His insights showcase how Novo Nordisk is innovating and collaborating to tackle significant health challenges.